[1] Roberts J M, August P A, Bakris G, et al. Hypertension in pregnancy report of the American College of Obstetricians and Gynecologists’ Task Force on hypertension in pregnancy[J]. Obstet Gynecol, 2013, 122(5): 1122-1131.
[2] American College of Obstetricians and Gynecologists. ACOG practice bulletin No.202 gestational hypertension and preeclampsia[J]. Obstet Gynecol, 2019, 133(1): e1-e25.
[3] Cruz-Lemini M, Vázquez J C, Ullmo J, et al. Low-molecular-weight heparin for prevention of preeclampsia and other placenta-mediated complications: a systematic review and meta-analysis[J]. Am J Obstet Gynecol, 2022, 226(2S): S1126-S1144.e17
[4] Cournot M, Lairez O, Medzech B. Preeclampsia: a challenge also for cardiologists[J]. Ann Cardiol Angeiol (Paris), 2018, 67(4): 280-287.
[5] Gris J C, Chauleur C, Molinari N, et al. Addition of enoxaparin to aspirin for the secondary prevention of placental vascular complications in women with severe pre-eclampsia. the pilot randomized controlled NOH-PE trial[J]. J Thromb Haemost, 2011, 106(6): 1053-1061.
[6] Rai R,Regan L. Recurrent miscarriage[J]. Lancet, 2006, 368(9535):601-611.
[7] Kingdom J C, Walke M, Proctor L K, et al. Unfractionated heparin for second trimester placental insufficiency: a pilot randomized trial[J]. J Thromb Haemost, 2011, 9(8): 1483-1492.
[8] Rahnemaei F A, Fashami M A, Abdi F, et al. Factors effective in the prevention of Preeclampsia: a systematic review[J]. Taiwan J Obstet Gynecol, 2020, 59(2):173-182.
[9] McLaughlin K, Scholten R R, Parker J D, et al. Low molecular weight heparin for the prevention of severe preeclampsia: where next?[J]. Br J Clin Pharmacol, 2018, 84(4): 673-678.
[10] 叶丽燕,范徐妃,郑秀娟.低分子肝素预防子痫前期的效果[J].中国妇幼保健, 2021, 36(24):5610-5612.
[11] Mello G, Parretti E, Fatini C, et al. Low-molecular-weigh theparin lowers the recurrence rate of preeclampsia and restores the physiological vascular changes in angiotensin-converting enzyme DD women[J] . Hypertension, 2005, 45(1): 86-91.
[12] Gris J C, Chauleur C, Molinari N, et al. Addition of enoxaparin to aspirin for the secondary prevention of placental vascular complications in women with severe pre-eclampsia. the pilot randomized controlled NOH-PE trial[J]. J Thromb Haemost, 2011, 106(6): 1053-1061.
[13] Groom K M, McCowan L M, Stone P R, et al. EPPI trial Study Group.Enoxaparin for the prevention of preeclampsia and intrauterine growth restriction in women with a prior history - an open-label randomised trial (the EPPI trial): study protocol[J].BMC Pregnancy Childbirth, 2016 16(1):367.
[14] Liu Y H, Zhang Y S, Chen J Y, et al. Comparative effectiveness of prophylactic strategies for preeclampsia: a network meta-analysis of randomized controlled trials[J]. Am J Obstet Gynecol, 2022.DOI:https://doi.org/10.1016/j.ajog.2022.10.014.
[15] Wu C, Li L, Zhang J, et al. Efficacy and safety of low-dose aspirin combined with low-molecular-weight heparin in treatment of preeclampsia: a meta-analysis and systematic review[J]. Arch Med Sci, 2021, 18(6):1525-1534.
[16] Wang X, Gao H. Prevention of preeclampsia in high-risk patients with low-molecular-weight heparin: a meta-analysis[J]. Matern Fetal Neonatal Med, 2020, 33(13): 2202-2208.
[17] Llurba E, Bella M, Burgos J, et al. Early prophylactic enoxaparin for the prevention of preeclampsia and intrauterine growth restriction: a randomized trial[J].Fetal Diagn Ther, 2020, 47(11):824-833.
[18] Groom K M,McCowan L M,Mackay L K,et al. Enoxaparin for the prevention of preeclampsia and intrauterine growth restriction in women with a history: a randomized trial[J]. Am J Obstet Gynecol, 2017, 216(3): 296.e1-296.
[19] Roberge S, Bujold E, Nicolaides K H. Aspirin for the prevention of preterm and term preeclampsia: systematic review and meta-analysis[J]. Am J Obstet Gynecol, 2018, 218 (3):287-293.e1.
[20] Roberge S, Nicolaides K, Demers S, et al. The role of aspirin dose on the prevention of preeclampsia and fetal growth restriction: systematic review and meta-analysis[J]. Am J Obstet Gynecol, 2017, 216 (2): 110-120.
[21] Meher S, Duley L, Hunter K, et al. Antiplatelet therapy before or after 16 weeks′ gestation for preventing preeclampsia: an individual participant data meta-analysis[J]. Am J Obstet Gynecol, 2017, 216(2):121-128.
[22] Roberge S, Bujold E, Nicolaides K H. Meta-analysis on the effect of aspirin use for prevention of preeclampsia on placental abruption and antepartum hemorrhage[J]. Am J Obstet Gynecol, 2018, 218 (5) : 483-489.
[23] 张芳飞,郑秀娟,范徐妃,等. 小剂量阿司匹林或联合低分子肝素预防子痫前期效果评价[J]. 浙江医学, 2018, 40(17):1918-1921.
[24] Marc A R, Jean-C G, Johanna I P, et al. Low-molecular-weight heparin and recurrent placenta-mediated pregnancy complications: a meta-analysis of individual patient data from randomzsed controlled trials[J]. Lancet, 2016, 388(10060): 2629-2641.
[25] 孙 卓,石 敏,李天爽,等.小剂量阿司匹林联合肝素预防子痫前期疗效的Meta分析[J].实用妇产科杂志, 2019, 35(7):522-527.
[26] Zheng L, Xia B, Yuan Y, et al. Low-molecular-weight heparin in addition to low-dose aspirin for preventing preeclampsia and its complications: a systematic review and meta-analysis[J]. Front Cardiovasc Med, 2022,9:1073148.
[27] 陈卫红,杨 楷.复方丹参注射液联合低分子肝素对早发型重度子痫前期孕妇心肾功能的影响及作用机制[J].中国计划生育学杂志,2019,27( 10) : 1321 -1325.
[28] 李 霞,杨玉秀,李 曼,等.低分子肝素对早发子痫前期妊娠结局影响的Meta分析[J].实用妇产科杂志,2018,34(4): 309-313.
[29] Edouard L, Jean C G, Eva C N, et al. Angiogenic factor profiles in pregnant women with a history of early-onset severe preeclampsia receiving low-molecular-weight heparin prophylaxis[J]. Obstet Gynecol, 2018, 131(1): 63-69.
[30] Haddad B, Winer N, Chitrit Y, et al. Enoxaparin and aspirin compared with aspirin alone to prevent placenta-mediated pregnancy complications: a randomized controlled trial[J]. Obstet Gynecol, 2016, 128(5):1053-1063.
[31] Vries J I, Pampus M G, Hague W M,et al. Lowmolecular-weight heparin added to aspirin in the prevention of recurrent early-onset preeclampsia in women with inheritable thrombophilia: the FRUIT-RCT[J]. J Thromb Haemost, 2012,10: 64-72.
[32] 赵先兰,徐艳霞,周 艳,等.应用低分子肝素对早发型子痫前期患者再次妊娠结局的影响[J].实用妇产科杂志,2018,34(2):135-138.
[33] Petri M. Pregnancy and systemic lupus erythematosus[J]. Best Pract Res Clin Obstet Gynaecol, 2020, 64: 24-30.
[34] Schreiber K, Sciascia S, Groot P G, et al. Antiphospholipid syndrome[J].Nat Rev Dis Primers, 2018, 4:17103.
[35] Middeldorp S, Naue C, Köhler C. Thrombophilia.thrombosis and thromboprophylaxis in pregnancy: for what and in whom?[J]. Hamostaseologie, 2022, 42(1): 54-64.
[36] Hamulyák E N, Scheres L J, Marijnen M C, et al. Aspirin heparin or both for improving pregnancy outcomes in women with persistent antiphospholipid antibodies and recurrent pregnancy loss[J]. Cochrane Database Syst Rev, 2020, 5(5): CD012852.
[37] Yang Z, Shen X, Zhou C, et al. Prevention of recurrent miscarriage in women with antiphospholipid syndrome: a systematic review and network meta-analysis[J].Lupus, 2021, 30(1):70-79.
[38] Kingdom J C, Drewlo S. Is heparin a placental anticoagulant in high-risk pregnancies?[J]. Blood, 2011, 118(18):4780-4788.
[39] North R A, Ferrier C, Gamble G, et al. Prevention of preeclampsia with heparin and antiplatelet drugs in women with renal disease[J]. Aust N Z J Obstet Gynaecol, 1995, 35(4):357-362.
[40] Karadag C, Akar B, Gonenc G, et al. Aspirin, low molecular weight heparin, or both in preventing pregnancy complications in women with recurrent pregnancy loss and factor V Leiden mutation[J]. Matern Fetal Neonatal Med, 2020, 33(11):1934-1939.
[41] Zullino S, Clemenza S, Mecacci F, et al. Low molecular weight heparins (LMWH) and implications along pregnancy: a focus on the placenta[J]. Reprod Sci, 2022, 29(5):1414-1423.
[42] Wat J M, Hawrylyshyn K, Baczyk D, et al. Effects of glycol-split low molecular weight heparin on placental, endothelial, and anti-inflammatory pathways relevant to preeclampsia[J]. Biol Reprod, 2018, 99(5): 1082-1090.
[43] Skeith L, Blondon M, Áinle F.Understanding and preventing placenta-mediated pregnancy complications[J]. Hamostaseologie, 2020, 40(3): 356-363.